HIV molecular immunology database
Found 1 matching record:
| HXB2 Location | Gag(180-188) | Gag Epitope Map
View variants at this location |
||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epitope |
TPQDLNTML
|
Epitope Alignment | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Variants |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Epitope Name | TL9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Species (MHC/HLA) | human(B*39:10, B*81:01) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Showing all: 17 variant(s).
| Variant ID. | 3155 |
|---|---|
| Epitope Seq. | TPQDLNTML{...I...A} |
| Variant Seq. | TPtDLNTML{...h...t} |
| Mutations | Q/T I/H A/T |
| Epitope Location | Q3T I+35H A+60T |
| HXB2 Location | Q182T I223H A248T |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182T had developed by 2 weeks post-infection , and putative compensatory mutations I223H and A248T had also developed by then in a B*8101-positive subject [Donor HLA = A*2601, A*8001, B*1801, B*8101, Cw*0202, Cw*0401; relatively high VL with CD4+ cell count increasing between years 3-4 post-infection] |
| Variant ID. | 3156 |
|---|---|
| Epitope Seq. | TPQDLNTML{...I...A} |
| Variant Seq. | TPsDLNTML{...h...t} |
| Mutations | Q/S I/H A/T |
| Epitope Location | Q3S I+35H A+60T |
| HXB2 Location | Q182S I223H A248T |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182S had developed by 32 weeks post-infection , and putative compensatory mutations I223H and A248T had also developed by then in a B*8101-positive subject [Donor HLA = A*2601, A*8001, B*1801, B*8101, Cw*0202, Cw*0401; relatively high VL with CD4+ cell count increasing between years 3-4 post-infection] |
| Variant ID. | 3157 |
|---|---|
| Epitope Seq. | TPQDLNTML{...I} |
| Variant Seq. | TPQDLNTML{...a} |
| Mutations | I/A |
| Epitope Location | I+35A |
| HXB2 Location | I223A |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation outside TL9, I223A had developed by 56 weeks post-infection in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts] |
| Variant ID. | 3158 |
|---|---|
| Epitope Seq. | TPQDLNTML{...I...I} |
| Variant Seq. | TPsDLNTML{...a...v} |
| Mutations | Q/S I/A I/V |
| Epitope Location | Q3S I+35A I+68V |
| HXB2 Location | Q182S I223A I256V |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182S, had developed by 83 weeks post-infection, and putative compensatory mutations I223A and I26V had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts] |
| Variant ID. | 3159 |
|---|---|
| Epitope Seq. | {E...}TPQDLNTML{...I} |
| Variant Seq. | {d...}aPsDLNsML{...a} |
| Mutations | T/A E/D Q/S I/A T/S |
| Epitope Location | T1A E-3D Q3S I+35A T7S |
| HXB2 Location | T180A E177D Q182S I223A T186S |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | Mutations within TL9, E177D, T180A, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations I223A had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts] |
| Variant ID. | 3160 |
|---|---|
| Epitope Seq. | {E...}TPQDLNTML{...I} |
| Variant Seq. | {d...}TPsDLNsML{...v} |
| Mutations | E/D Q/S I/V T/S |
| Epitope Location | E-3D Q3S I+35V T7S |
| HXB2 Location | E177D Q182S I223V T186S |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | Mutations within TL9, E177D, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations I223V had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts]. The very same set of mutations developed in a B*3910-positive subject too, by 9 weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection] |
| Variant ID. | 3161 |
|---|---|
| Epitope Seq. | {E...}TPQDLNTML{...H...I} |
| Variant Seq. | {d...}TPsDLNsML{...q...v} |
| Mutations | E/D Q/S H/Q I/V T/S |
| Epitope Location | E-3D Q3S H+31Q I+35V T7S |
| HXB2 Location | E177D Q182S H219Q I223V T186S |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | Mutations within TL9, E177D, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations H219Q, I223V had also developed by then in a B*3910-positive subject, by 85 weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection] |
| Variant ID. | 3162 |
|---|---|
| Epitope Seq. | TPQDLNTML{...I...I} |
| Variant Seq. | TPaDLNTML{...v...v} |
| Mutations | Q/A I/V I/V |
| Epitope Location | Q3A I+35V I+68V |
| HXB2 Location | Q182A I223V I256V |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182A had developed by 8 weeks post-infection, and putative compensatory mutations I223V and !256V had also developed by then in a B*3910-positive subject, weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection] |
| Variant ID. | 3163 |
|---|---|
| Epitope Seq. | TPQDLNTML{...I...I} |
| Variant Seq. | TPgDLNTML{...v...v} |
| Mutations | Q/G I/V I/V |
| Epitope Location | Q3G I+35V I+68V |
| HXB2 Location | Q182G I223V I256V |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182G had developed by 28 weeks post-infection, and putative compensatory mutations I223V and I256V had also developed by then in a B*3910-positive subject [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection] |
| Variant ID. | 3164 |
|---|---|
| Epitope Seq. | TPQDLNTML{...M} |
| Variant Seq. | TPhDLNTML{...i} |
| Mutations | Q/H M/I |
| Epitope Location | Q3H M+62I |
| HXB2 Location | Q182H M250I |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182H, had developed by 50 weeks post-infection, and a putative compensatory mutation, M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor]. |
| Variant ID. | 3165 |
|---|---|
| Epitope Seq. | TPQDLNTML{...M} |
| Variant Seq. | TPtDLNTML{...i} |
| Mutations | Q/T M/I |
| Epitope Location | Q3T M+62I |
| HXB2 Location | Q182T M250I |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182T, had developed by 54 weeks post-infection, and a putative compensatory mutation, M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor]. |
| Variant ID. | 3166 |
|---|---|
| Epitope Seq. | TPQDLNTML{...M} |
| Variant Seq. | TPaDLNTML{...i} |
| Mutations | Q/A M/I |
| Epitope Location | Q3A M+62I |
| HXB2 Location | Q182A M250I |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182A, had developed by 71 weeks post-infection, and a putative compensatory mutation, M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor]. |
| Variant ID. | 3167 |
|---|---|
| Epitope Seq. | TPQDLNTML{...M} |
| Variant Seq. | TPsDLNTML{...i} |
| Mutations | Q/S M/I |
| Epitope Location | Q3S M+62I |
| HXB2 Location | Q182S M250I |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182S, had developed by 84 weeks post-infection, and a putative compensatory mutation, M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor]. |
| Variant ID. | 3168 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPsDLNsML |
| Mutations | Q/S T/S |
| Epitope Location | Q3S T7S |
| HXB2 Location | Q182S T186S |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | Mutations within TL9, Q182S and T186S had developed by 97 weeks post-infection in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor]. |
| Variant ID. | 3169 |
|---|---|
| Epitope Seq. | TPQDLNTML{...A} |
| Variant Seq. | TPsDLNsML{...t} |
| Mutations | Q/S A/T T/S |
| Epitope Location | Q3S A+60T T7S |
| HXB2 Location | Q182S A248T T186S |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | Mutations within TL9, Q182S and T186S had developed by 110 weeks post-infection, as well as a putative compensatory mutation at A248T in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor]. |
| Variant ID. | 3170 |
|---|---|
| Epitope Seq. | TPQDLNTML{...I} |
| Variant Seq. | TPtDLNTML{...v} |
| Mutations | Q/T I/V |
| Epitope Location | Q3T I+68V |
| HXB2 Location | Q182T I256V |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, Q182T, had developed by 53 weeks post-infection, and putative compensatory mutation I256V had also developed by then in a B*4201-positive subject. |
| Variant ID. | 3171 |
|---|---|
| Epitope Seq. | TPQDLNTML{...H...I...M} |
| Variant Seq. | TPQDLNTMf{...q...v...i} |
| Mutations | H/Q I/V M/I L/F |
| Epitope Location | H31Q I35V M62I L9F |
| HXB2 Location | H219Q I223V M250I L188F |
| Mutation Type | OV: observed variant |
| Epitope Subtype | C |
| Variant Subtype | C |
| Method | Sequence |
| Note | A mutation within TL9, L188F had developed by 76 weeks post-infection, and putative compensatory mutations H219Q, I223V and M250I had also developed by then in a B*4201, Cw*0802-positive subject |
Ntale2012 R. S. Ntale, D. R. Chopera, N. K. Ngandu, D. Assis de Rosa, L. Zembe, H. Gamieldien, M. Mlotshwa, L. Werner, Z. Woodman, K. Mlisana, S. Abdool Karim, C. M. Gray, C. Williamson, and CAPRISA 002 Study Team. Temporal Association of HLA-B*81:01- and HLA-B*39:10-Mediated HIV-1 p24 Sequence Evolution with Disease Progression. J. Virol., 86(22):12013-12024, Nov 2012. PubMed ID: 22933291. Show all entries for this paper.